Jazz Pharmaceuticals plc (JAZZ) Financial Statements
Jazz Pharmaceuticals plc (JAZZ) reported trailing twelve-month revenue of $4.6B (up 12.6% year on year) and net income of $940.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.4B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
JAZZJazz Pharmaceuticals plcFollow JAZZ — free
—
Price chart with a free account
- Market cap
- 13.9B
- P/E TTM
- 14.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.27 | 0.59 | 0.87 | 1.17 | 1.32 | 1.49 | 1.62 | 1.89 | 2.16 | 2.36 | 3.09 | 3.66 | 3.83 | 4.07 | 4.27 | 4.60 | |
| Gross profit | — | — | — | — | — | — | — | — | 1.57 | 1.23 | 1.62 | 1.35 | 1.92 | 2.10 | 1.38 | 2.58 | |
| Research & development | 0.01 | 0.02 | 0.04 | 0.09 | 0.14 | 0.16 | 0.20 | 0.23 | 0.30 | 0.34 | 0.51 | 0.59 | 0.85 | 0.88 | 0.78 | 0.82 | |
| Operating income | 0.13 | 0.20 | 0.34 | 0.20 | 0.51 | 0.59 | 0.53 | 0.61 | 0.53 | 0.38 | 0.17 | -0.07 | 0.58 | 0.72 | -0.43 | 0.90 | |
| Pre-tax income | 0.12 | 0.18 | 0.31 | 0.15 | 0.44 | 0.53 | 0.44 | 0.53 | 0.45 | 0.28 | -0.11 | -0.37 | 0.30 | 0.47 | -0.63 | 0.73 | |
| Income tax | 0.00 | -0.08 | 0.09 | 0.09 | 0.11 | 0.14 | -0.05 | 0.08 | -0.07 | 0.03 | 0.22 | -0.16 | -0.12 | -0.09 | -0.27 | -0.21 | |
| Net income | 0.12 | 0.29 | 0.22 | 0.06 | 0.33 | 0.40 | 0.49 | 0.45 | 0.52 | 0.24 | -0.33 | -0.22 | 0.41 | 0.56 | -0.36 | 0.94 | |
| Diluted EPS ($) | 2.67 | 4.79 | 3.51 | 0.93 | 5.23 | 6.41 | 7.96 | 7.30 | 9.09 | 4.22 | -5.52 | -3.58 | 6.10 | 8.65 | -5.84 | 14.63 | |
| Diluted shares (bn) | 0.047 | 0.060 | 0.062 | 0.063 | 0.063 | 0.062 | 0.061 | 0.061 | 0.058 | 0.057 | 0.060 | 0.063 | 0.072 | 0.066 | 0.061 | — |
USD billions · SEC XBRL
Jazz Pharmaceuticals plc — questions
- What is Jazz Pharmaceuticals plc's revenue?
- $4.6B over the twelve months to 2026-06-30, up 12.6% year on year, from its 10-Q and 10-K filings.
- What is Jazz Pharmaceuticals plc's net income?
- $940.8M over the twelve months to 2026-06-30.
- What is Jazz Pharmaceuticals plc's free cash flow?
- $1.4B over the twelve months to 2026-06-30.
- What are Jazz Pharmaceuticals plc's diluted earnings per share?
- $14.63 over the twelve months to 2026-06-30.
Every figure on this page comes from Jazz Pharmaceuticals plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.